Inflammatory pulmonary diseases such as asthma and chronic obstructive pulmonary disease (COPD) remain major global health burdens characterized by chronic airway inflammation, airflow obstruction and frequent exacerbations. Current standard treatments—including inhaled corticosteroids and bronchodilators—can provide symptomatic relief but are limited by incomplete efficacy in severe disease and systemic adverse effects. Biologic therapies that target type 2 (T2) inflammatory pathways reduce exacerbations in some patients but achieve modest remission rates and are less effective in T2-low phenotypes. Thus, there is a persistent need for novel therapeutic approaches that can address airway inflammation across diverse inflammatory endotypes.
The receptor for advanced glycation end products (RAGE, gene AGER) is a multiligand pattern-recognition receptor highly expressed on alveolar type-1 epithelial cells. RAGE binds damage-associated molecular patterns including advanced glycation end-products, HMGB1, complement fragments and S100 proteins. Activation of RAGE engages intracellular pathways such as NF-κB, MAPK and JAK/STAT, amplifying innate immune responses. Preclinical studies have implicated RAGE in both T2-driven and non–T2 inflammatory processes: RAGE is necessary for airway influx of IL-33, IL-5, IL-13 and eosinophils in allergic models and contributes to inflammasome activation and neutrophil recruitment in neutrophilic airway disease models. RAGE knockout animals are protected from inflammatory injury and parenchymal destruction in several COPD/emphysema models, supporting RAGE as a candidate therapeutic target across multiple pulmonary inflammatory phenotypes.
To directly reduce RAGE expression, the investigators developed ARO-RAGE, a synthetic double-stranded small interfering RNA (siRNA) designed to silence AGER mRNA via RNA interference. The siRNA is conjugated to a targeting ligand selective for epithelial ανβ6 integrins, a strategy intended to facilitate selective uptake by pulmonary epithelial cells after inhaled administration. This targeted lung delivery platform aims to maximize pulmonary target engagement while limiting systemic exposure.
Preclinical studies across species supported the approach. In rat studies, a species-specific siRNA conjugated to an ανβ6-selective ligand showed predominant pulmonary distribution after inhalation and achieved deep, durable silencing of RAGE. In rat models of allergic asthma, COPD and acute lung injury, silencing of pulmonary RAGE limited inflammatory responses. Mouse models evaluating inflammatory pathways similarly demonstrated reduced inflammatory mediators and cellular influx with RAGE inhibition. The provided extract references supplementary data for tissue distribution but truncates before full quantitative details; specific doses and magnitude of effect were not reported in the provided text.
In macaques, inhaled ARO-RAGE produced dose-dependent reductions in membrane-bound RAGE levels in lung tissue and decreases in soluble RAGE (sRAGE) measured in serum. Bronchoalveolar lavage (BAL) obtained after dosing showed post-dose reductions in sRAGE, consistent with robust silencing of membrane-bound pulmonary RAGE and local target engagement in the lung compartment.
The clinical program progressed to a phase 1/2a randomized, double-blind, placebo-controlled trial (ClinicalTrials.gov NCT05276570) designed to assess safety and tolerability as the primary endpoint, pharmacokinetics as a secondary endpoint, and pharmacodynamics as an exploratory endpoint. The trial included two cohorts reported in the extract: healthy volunteers (total n = 58; male n = 14) and patients with asthma (total n = 19; male n = 6). The provided text does not include full enrollment criteria, dosing cohorts, treatment schedules or exact randomization ratios; those details were not reported in the source extract available here.
In both healthy volunteers and patients with asthma, inhaled ARO-RAGE was reported as safe and well tolerated. No clinically relevant changes were observed in chest x-ray findings, pulmonary function tests or systemic markers of inflammation across the two cohorts described. The extract does not include a detailed adverse event table, rates of treatment-emergent events, or serious adverse event descriptions; such granular safety data were not reported in the provided text.
Plasma concentrations of ARO-RAGE were low post-dose, interpreted as consistent with lung retention of the therapeutic and minimal systemic bioavailability. Pharmacodynamic evidence of pulmonary target engagement included prolonged, dose-responsive decreases in serum and BAL sRAGE levels following inhalation. These biomarker changes were presented as supportive of effective pulmonary RAGE silencing; however, exact magnitude, time-course, and relationship to clinical endpoints were not detailed in the extract.
The combined preclinical and early clinical data reported support the feasibility of pulmonary delivery of an epithelial-targeted therapeutic siRNA and demonstrate biochemical target engagement of RAGE in the lung. ARO-RAGE reduced RAGE expression in animal models and produced dose-responsive reductions in sRAGE in macaques and in human BAL and serum, while showing a favorable early safety profile in healthy volunteers and patients with asthma. These results, as summarized in the provided extract, support continued clinical development of ARO-RAGE for inflammatory pulmonary diseases across potential T2-high and T2-low phenotypes.
The source text provided here is truncated and lacks many important granular data points: specific dosing regimens, numerical pharmacokinetic parameters, detailed adverse event frequencies and severities, statistical analyses, and longer-term follow-up. Where those details are required for decision-making or deep interpretation, they were not reported in the provided extract and should be retrieved from the full published article or trial registry.